Co-administered antibiotics at the level of bacterial response

The term "Co-administered antibiotics at the level of bacterial response" does not refer to a single molecular target, such as a protein or receptor, but rather describes a pharmacological strategy and the resulting physiological state of a pathogen under multi-drug pressure. This approach leverages the interactions between different antimicrobial mechanisms to enhance killing efficacy or overcome resistance mechanisms (Tyers & Wright, 2019, Nature Reviews Microbiology). At the bacterial level, these combinations can result in synergy, where the combined effect is greater than the sum of individual effects, or antagonism, where one drug interferes with the action of another (Bollenbach, 2015, Current Opinion in Microbiology). Clinically, co-administration is a cornerstone in treating complex infections like tuberculosis or those caused by multi-drug resistant Gram-negative bacteria. The bacterial response to these combinations involves complex metabolic rewiring and the activation of diverse stress-response pathways, which are studied to optimize dosing regimens and predict clinical outcomes (Doern, 2014, Journal of Clinical Microbiology). Because this entry represents a therapeutic modality rather than a discrete biological entity, it is classified as an incorrect target designation for molecular drug discovery purposes.

Other names

Antibiotic combination therapyAntibiotic synergyBacterial response to antibiotic combinationsPolypharmacy in bacterial infectionsCombinatorial antimicrobial therapy

The mechanism involves the simultaneous targeting of multiple independent or sequential biochemical pathways within a bacterium to achieve a greater-than-additive effect (synergy), prevent the emergence of resistant mutants, or inhibit bacterial enzymes that would otherwise degrade the primary antibiotic (e.g., beta-lactamase inhibitors).